{
    "organizations": [],
    "uuid": "016b2be976cad36e68734a379d7cf13f3908bc00",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-macrogenics-announces-continuation/brief-macrogenics-announces-continuation-of-sophia-study-of-margetuximab-based-on-completion-of-interim-futility-analysis-idUSFWN1PI19C",
    "ord_in_thread": 0,
    "title": "BRIEF-Macrogenics Announces Continuation Of Sophia Study Of Margetuximab Based On Completion Of Interim Futility Analysis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 23 (Reuters) - Macrogenics Inc:\n* MACROGENICS ANNOUNCES CONTINUATION OF SOPHIA STUDY OF MARGETUXIMAB BASED ON COMPLETION OF INTERIM FUTILITY ANALYSIS\n* MACROGENICS INC - U.S. FDA HAS GRANTED FAST TRACK DESIGNATION FOR INVESTIGATION OF MARGETUXIMAB\n* MACROGENICS - GRANTED FAST TRACK DESIGNATION FOR INVESTIGATION OF MARGETUXIMAB FOR TREATMENT OF PATIENTS WITH METASTATIC/ LOCALLY ADVANCED HER2 POSITIVE BREAST CANCER\n* MACROGENICS INC - ANNOUNCED COMPLETION OF A PRE-PLANNED INTERIM FUTILITY ANALYSIS OF PHASE 3 SOPHIA TRIAL\n* MACROGENICS INC - AN INDEPENDENT DATA SAFETY MONITORING COMMITTEE (DSMC) HAS RECOMMENDED THAT SOPHIA STUDY CONTINUE AS PLANNED WITHOUT MODIFICATION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-24T06:09:00.000+02:00",
    "crawled": "2018-01-24T15:52:14.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "macrogenics",
        "inc",
        "macrogenics",
        "announces",
        "continuation",
        "sophia",
        "study",
        "margetuximab",
        "based",
        "completion",
        "interim",
        "futility",
        "analysis",
        "macrogenics",
        "inc",
        "fda",
        "granted",
        "fast",
        "track",
        "designation",
        "investigation",
        "margetuximab",
        "macrogenics",
        "granted",
        "fast",
        "track",
        "designation",
        "investigation",
        "margetuximab",
        "treatment",
        "patient",
        "locally",
        "advanced",
        "her2",
        "positive",
        "breast",
        "cancer",
        "macrogenics",
        "inc",
        "announced",
        "completion",
        "interim",
        "futility",
        "analysis",
        "phase",
        "sophia",
        "trial",
        "macrogenics",
        "inc",
        "independent",
        "data",
        "safety",
        "monitoring",
        "committee",
        "dsmc",
        "recommended",
        "sophia",
        "study",
        "continue",
        "planned",
        "without",
        "modification",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}